Sunlink Hlth Stock Price, News & Analysis

SunLink Health Systems (NYSE American: SSY) is urging stockholders to vote in favor of its proposed merger with Regional Health Properties before the July 28, 2025, 11:59 PM EDT deadline. Over 99% of voted shares support the merger, but additional votes are needed to meet the required majority threshold of outstanding shares.

The special stockholder meeting is scheduled for July 29, 2025, at 10:00 AM EDT. Leading proxy advisor ISS has recommended voting FOR the merger, citing the board's review of alternatives and potential upside for stockholders. The merger aims to combine SunLink's pharmacy operations with Regional's nursing home and healthcare real estate operations to achieve vertical integration and operational efficiencies.

SunLink Health Systems (NYSE American: SSY) has provided an update regarding its previously announced $0.10 per share special cash dividend related to its proposed merger with Regional Health Properties. The dividend will have a due bill period from July 29, 2025 (record date) through July 30, 2025 (payment date).

During this period, buyers of SSY stock will be entitled to receive the Special Cash Dividend, while sellers will not. Investors must hold the stock through the payment date of July 30, 2025, to receive the dividend. The due bill obligations will be settled between brokers representing buyers and sellers.

The company emphasized that this communication does not constitute an offer to sell securities and directed investors to review the Registration Statement on Form S-4 and joint proxy statement/prospectus for complete merger details.

SunLink Health Systems (NYSE American: SSY) has declared a special cash dividend of $0.10 per share ahead of its proposed merger with Regional Health Properties. The dividend, totaling approximately $704,600, will be paid on July 30, 2025, to stockholders of record as of July 29, 2025.

The dividend declaration is contingent on several conditions, including merger approval at the Special Meeting of Shareholders on July 29, 2025. The merger completion requires shareholder approvals from both companies, regulatory clearances, and NYSE American listing authorization for Regional's common and preferred stock.

The special dividend is expected to be characterized as a return of capital rather than a dividend distribution, as SunLink does not anticipate having current or accumulated earnings and profits as defined by the Internal Revenue Code.

SunLink Health Systems (NYSE American: SSY) has received a deficiency notice from NYSE American for failing to hold its annual stockholders meeting for the fiscal year ending June 30, 2025. While the company's stock will continue trading, it will be assigned a ".BC" indicator to show non-compliance with listing standards.

The notice does not impact SunLink's planned merger with Regional Health Properties, scheduled for shareholder approval at a special meeting on July 29, 2025. If the merger agreement is terminated, SunLink plans to hold its annual meeting by June 30, 2026, to regain compliance. The merger agreement can be terminated if not consummated by August 11, 2025.

SunLink Health Systems (NYSE American: SSY) reported its fiscal 2025 third quarter results, showing a loss from continuing operations of $630,000 ($0.09 per share) compared to $824,000 ($0.12 per share) in the same quarter last year. Net loss improved to $671,000 from $1,396,000 year-over-year. Consolidated revenues were $7,323,000, down slightly from $7,462,000, primarily from pharmacy operations. Notably, pharmacy revenues increased 1% due to higher institutional pharmacy sales. The company announced a merger agreement with Regional Health Properties, where SunLink shareholders will receive approximately 1.6M shares of Regional common stock and 1.4M shares of Series D Preferred Stock. The company continues to face post-COVID challenges including wage pressure, workforce shortages, and supply chain disruptions.

SunLink Health Systems (NYSE American: SSY) reported its fiscal 2025 second quarter results, showing a loss from continuing operations of $1,070,000 ($0.15 per share) compared to $407,000 ($0.06 per share) in the same quarter last year. The company's consolidated net revenues decreased to $7,935,000 from $8,510,000, primarily due to lower pharmacy revenues.

The company announced a definitive merger agreement with Regional Health Properties on January 3, 2025, which will involve exchanging shares for 1,410,000 shares of Regional common stock and 1,410,000 shares of Series D 8% Cumulative Convertible Redeemable Preferred Stock. The merger requires shareholder and regulatory approvals.

SunLink continues to experience post-COVID-19 effects, including wage pressure, workforce shortages, supply chain disruption, and inflationary pressures. The company also recorded a $100,000 impairment loss related to its information technology business, which was sold in January 2025.

SunLink Health Systems (NYSE American: SSY) reported Q1 fiscal 2025 results with a loss from continuing operations of $442,000 ($0.06 per share), compared to $428,000 loss in Q1 2024. The company sold non-core assets for $1,465,000, resulting in a $694,000 pre-tax gain. Net loss was $549,000 ($0.08 per share), improved from $1,344,000 loss year-over-year. Consolidated revenues decreased to $7,923,000 from $8,555,000, with pharmacy revenues declining 7%. The company's operating loss widened to $1,194,000 from $450,000 due to decreased revenues and higher operating costs. The Board is actively pursuing extraordinary corporate transactions, including potential mergers.

SunLink Health Systems, Inc. (NYSE AMERICAN: SSY) has announced the completion of the sale of its formerly operated Trace Regional Hospital real estate in Houston, Mississippi. The transaction, executed by its subsidiary Southern Health of Houston, Inc., and an affiliate, yielded approximately $2,000,000, with net proceeds of about $1,932,000 to be retained for working capital and general corporate purposes.

The company anticipates recognizing a pre-tax loss of approximately $91,000 on the sale in its second fiscal quarter ending December 31, 2024. This strategic move aligns with SunLink's goal of positioning itself for a potential extraordinary transaction, as it seeks to identify opportunities that could offer shareholders future value appreciation at an acceptable risk level.

SunLink Health Systems (NYSE American: SSY) reported financial results for Q4 and FY 2024. Key highlights include:

- Q4 loss from continuing operations: $652,000 ($0.09 per share)

- Q4 earnings from discontinued operations: $4,940,000 ($0.70 per share)

- Q4 net income: $4,288,000 ($0.61 per share)

- FY 2024 loss from continuing operations: $2,311,000 ($0.33 per share)

- FY 2024 net loss: $1,527,000 ($0.22 per share)

- Sale of Trace Extended Care & Rehab for $6,522,000, with a gain of $5,584,000

- Revised agreement for sale of Trace Hospital Assets

- Consolidated net revenues for Q4: $7,913,000

- Consolidated net revenues for FY 2024: $32,440,000

The company continues to experience adverse effects from the COVID-19 pandemic, including workforce shortages and inflationary pressures.